Difference between revisions of "Work Product for Review"

From QIBA Wiki
Jump to navigation Jump to search
(6 intermediate revisions by 2 users not shown)
Line 1: Line 1:
−
==Public Comment on QIBA Profiles and Protocols==
+
QIBA '''[[Profiles|Profile documents]]''' are posted for '''[[Public Comment Process|Public Comment]]''' to ensure stakeholder representation, transparency and quality review. Interested people are encouraged to provide input on the document, the scenarios and use cases they address, the technologies proposed and other details.   
−
QIBA documents are posted for Public Comment to ensure stakeholder representation, transparency and quality review. Interested people are encouraged to provide input on the document, the scenarios and use cases they address, the technologies proposed and other details. 
 
−
 
 
−
The [[Committees|QIBA Biomarker Committees]] consider all comments submitted, and where appropriate, post responses.   
 
  
 
==Comment Submission==
 
==Comment Submission==
Line 10: Line 7:
 
:* Provide your name or initials
 
:* Provide your name or initials
 
:* Follow the other instructions on the page
 
:* Follow the other instructions on the page
 +
:* CLICK SUBMIT
 
* e-mail ([mailto:sweinmann@rsna.org Susan Weinmann]) with ''general comments'' about the Profile/Protocol concept, structure, process, etc.
 
* e-mail ([mailto:sweinmann@rsna.org Susan Weinmann]) with ''general comments'' about the Profile/Protocol concept, structure, process, etc.
  
 +
The [[Committees|QIBA Biomarker Committees]] consider all comments submitted, and where appropriate, post responses. 
  
−
==QIBA Profiles and Protocols for Reference==
+
==Public Comment Documents==
−
 
 
−
*[[Media:001.QIBA SPECT Profile.v0.1 2016.10.28.docx | QIBA Profile: <big><font color=red> QIBA Profile: Quantifying Dopamine Transporters with 123 - Iodine Labeled Ioflupane in Neurodegenerative Disease Profile (v1.0), October 28, 2016</font></big>]] ''The Public Comment period ends February 1, 2017.''
 
−
 
 
−
*[[Media:002.QIBA SPECT Profile Checklist Extract.2016 10 31.docx|QIBA SPECT Profile Conformance Checklist]]
 
−
 
 
−
 
 
−
*[[Media:QIBA_CT_Vol_LungNoduleAssessmentInCTScreening_v5-2-16b.docx|QIBA Profile: <big><font color=red> QIBA Profile: Lung Nodule Volume Assessment and Monitoring in Low Dose CT Screening, June 1, 2016</font></big>]] ''The Public Comment period has closed''
 
−
 
 
−
*[[Media:QIBA Small Nodule Profile References - Accuracy.xlsx|QIBA Spreadsheet: <big><font color=red> Small Nodule Profile References_Accuracy. Version for Public Comment. June 1, 2016 </font></big>]] ''The Public Comment period has closed''
 
  
−
*[[Media:QIBA Small Nodule Profile References - Precision.xlsx|QIBA Spreadsheet: <big><font color=red> Small Nodule Profile References_Precision. Version for Public Comment. June 1, 2016 </font></big>]] ''The Public Comment period has closed''
+
see http://qibawiki.rsna.org/index.php/Profiles
  
  
 
*[[Document Archive]]
 
*[[Document Archive]]

Revision as of 22:53, 23 June 2017

QIBA Profile documents are posted for Public Comment to ensure stakeholder representation, transparency and quality review. Interested people are encouraged to provide input on the document, the scenarios and use cases they address, the technologies proposed and other details.

Comment Submission

  • Select the document you are commenting on from the dropdown menu
  • Provide your name or initials
  • Follow the other instructions on the page
  • CLICK SUBMIT
  • e-mail (Susan Weinmann) with general comments about the Profile/Protocol concept, structure, process, etc.

The QIBA Biomarker Committees consider all comments submitted, and where appropriate, post responses.

Public Comment Documents

see http://qibawiki.rsna.org/index.php/Profiles


Retrieved from "https://qibawiki.rsna.org/index.php?title=Work_Product_for_Review&oldid=11363"